ReversingLRP5-Dependent Osteoporosis andSOSTDeficiency-Induced Sclerosing Bone Disorders by Altering WNT Signaling Activity

WNT1 Mutations in Families Affected by Moderately Severe and Progressive Recessive Osteogenesis Imperfecta

(2013) Shawna M. Pyott et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Mutations in WNT1 Cause Different Forms of Bone Fragility

(2013) Katharina Keupp et al.   AMERICAN JOURNAL OF HUMAN GENETICS

An RNA-seq protocol to identify mRNA expression changes in mouse diaphyseal bone: Applications in mice with bone property alteringLrp5mutations

(2013) Ugur M Ayturk et al.   JOURNAL OF BONE AND MINERAL RESEARCH

WNT signaling in bone homeostasis and disease: from human mutations to treatments

(2013) Roland Baron et al.   NATURE MEDICINE

WNT1 Mutations in Early-Onset Osteoporosis and Osteogenesis Imperfecta

(2013) Christine M. Laine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lrp5 and Lrp6 Exert Overlapping Functions in Osteoblasts during Postnatal Bone Acquisition

(2013) Ryan C. Riddle et al.   PLoS One

Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling

(2013) Maarten van Dinther et al.   PLoS One

Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity

(2012) Johanna Korvala et al.   BMC Medical Genetics

Characterization of the Interaction of Sclerostin with the Low Density Lipoprotein Receptor-related Protein (LRP) Family of Wnt Co-receptors

(2012) Gill Holdsworth et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee

(2012) David W Dempster et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

(2012) A. Gurney et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

LRP5 and LRP6 in development and disease

(2012) Danese M. Joiner et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Sclerostin: Therapeutic Horizons Based Upon Its Actions

(2012) Aline G. Costa et al.   Current Osteoporosis Reports

The sclerostin-bone protein interactome

(2011) Hemamalini Devarajan-Ketha et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Structural Basis of Wnt Signaling Inhibition by Dickkopf Binding to LRP5/6

(2011) Victoria E. Ahn et al.   DEVELOPMENTAL CELL

Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia

(2011) Su Jin Kim et al.   HUMAN GENETICS

Bone Overgrowth-associated Mutations in theLRP4Gene Impair Sclerostin Facilitator Function

(2011) Olivier Leupin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma

(2011) Henrique Pierotti Arantes et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Lrp5 functions in bone to regulate bone mass

(2011) Yajun Cui et al.   NATURE MEDICINE

Crystal structures of the extracellular domain of LRP6 and its complex with DKK1

(2011) Zhihong Cheng et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Wnt Antagonists Bind through a Short Peptide to the First β-Propeller Domain of LRP5/6

(2011) Eric Bourhis et al.   STRUCTURE

Sclerostin–erbB-3 interactions: Modulation of erbB-3 activity by sclerostin

(2010) Theodore A. Craig et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Genetic evidence that SOST inhibits WNT signaling in the limb

(2010) Nicole M. Collette et al.   DEVELOPMENTAL BIOLOGY

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

(2010) Desmond Padhi et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Osteocyte Wnt/ -Catenin Signaling Is Required for Normal Bone Homeostasis

(2010) I. Kramer et al.   MOLECULAR AND CELLULAR BIOLOGY

Wnt Isoform-Specific Interactions with Coreceptor Specify Inhibition or Potentiation of Signaling by LRP6 Antibodies

(2010) Yan Gong et al.   PLoS One

Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies

(2010) S. A. Ettenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Parathyroid hormone (PTH)–induced bone gain is blunted in SOST overexpressing and deficient mice

(2009) Ina Kramer et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Novel Wnt antagonists target porcupine and Axin

(2009) Jing-Ruey J Yeh et al.   Nature Chemical Biology

The role of Dickkopf-1 in bone development, homeostasis, and disease

(2008) J. J. Pinzone et al.   BLOOD

Osteoporosis-pseudoglioma syndrome: Description of 9 new cases and beneficial response to bisphosphonates

(2008) Elizabeth A. Streeten et al.   BONE

The Binding Between Sclerostin and LRP5 is Altered by DKK1 and by High-Bone Mass LRP5 Mutations

(2008) Wendy Balemans et al.   CALCIFIED TISSUE INTERNATIONAL

Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum

(2008) Vijay K. Yadav et al.   CELL

Lrp6 Hypomorphic Mutation Affects Bone Mass Through Bone Resorption in Mice and Impairs Interaction With Mesd

(2008) Takuo Kubota et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength

(2008) Xiaodong Li et al.   JOURNAL OF BONE AND MINERAL RESEARCH